WHO WE ARE
Nucleic Capital is a specialist biotechnology investment firm based in the Channel Islands. Our focus is on investing in listed equities globally, targeting opportunities where technology advancements intersect with healthcare and synthetic biology.
OUR MISSION
Investing in the Future of Biotechnology
Over the coming decades, the bio economy is set to transform traditional industries, international supply chains and life itself. Whilst Nucleic shall invest in the emerging synthetic biology technology stack, underlying this transformation, the first wave of change is in healthcare. Reviewing the short term opportunities for growth over the coming decade, advances in synthetic biology and applied AI will deliver substantial success to well placed biotech, Pharma and software enabling technologies.
